Marker today announced interim data from an ongoing investigator-sponsored clinical trial led by Baylor College of Medicine, evaluating the Company’s MultiTAA T cell therapy in patients with pancreatic adenocarcinoma. The data were reviewed today in an oral presentation during a plenary session, as well as a poster presentation, at the American Association for Cancer Research’s (AACR) Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy conference held in San Francisco, California from July 19-22, 2019.
…JACKSONVILLE, Fla., Nov. 3, 2016 /PRNewswire/ — TapImmune, Inc., (TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced that its common stock has been approved to begin trading on The Nasdaq Capital Market. The company’s common stock will begin trading under the symbol “TPIV” at the opening of trading on Tuesday, November 8, 2016.
Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials
SEATTLE, July 27, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has exercised its option agreement with Mayo Clinic.
…Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox.
SEATTLE, WASHINGTON, October 22, 2014 — TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.